NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY;OSAKA UNIVERSITY;MITSUBISHI TANABE PHARMA CORPORATION
发明人:
HASHIMOTO, Motonori,YAMASHITA, Toshihide
申请号：
PE2017002320
公开号：
PE20180251A1
申请日:
2016.04.27
申请国别(地区):
PE
年份:
2018
代理人:
摘要：
Refers to the molecular conduit of polymeric protein A (insulating organic matter)It does not inhibit the association between RGMa and new genina, but neutralizes the neutron growth inhibition activity of organic compounds, It is better to provide an anti organic antibody, which has complementary determining region, including the sequence of CAS No. 30-35 or CAS No. 36-40 and SFG. Tools used to prevent, treat or prevent the recurrence of neurological or immune diseases, such as meningitis, cerebral palsy, multiple sclerosis, optical neurophobia, etc. He also mentioned a drug synthesis, a nucleic acid molecule, a recombinant vector,-A hospital cell and a method to product the coin proteine to RGM-A.Referido a una proteina de union a Molecula Guia Repelente A (RGMa aislada), que no inhibe la union entre la Molecula Guia Repelente a (RGMa) y neogenina pero neutraliza la actividad inhibidora del crecimiento neutritico de RGMa, preferiblemente proporcionando un anticuerpo anti-RGMa que tiene regiones determinantes de complementariedad que tienen secuencias de aminoacidos de SEQ ID NOS: 30-35 o SEQ ID NO: 36-40 en el listado de secuencias, y SFG. Utiles para prevenir, tratar o prevenir la recaida de enfermedades neurologicas o inmunologicas, tales como: lesion del plexo braquial, paralisis cerebral, esclerosis multiple, neuromielitis optica entre otros. Tambien se refiere a una composicion farmaceutica, una molecula de acido nucleico, un vector recombinante, una celula hospedera y un metodo para producir la proteina de union a RGM-a.
